PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 5, 2025New England Journal of Medicine0 citations

Impact of Ticagrelor Plus Aspirin on Outcomes After CABG for Acute Coronary Syndrome

Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAnders JeppssonSahlgrenska University HospitalSJStefan JamesCMChristian H. Møller

Discussion

Loading...

Member takes

Overview

Open-label trial analyzed adverse cardiovascular outcomes after CABG in patients receiving ticagrelor and aspirin, suggesting similar outcomes to aspirin alone.

Key Points

  • Ticagrelor plus aspirin did not lower death, myocardial infarction, stroke, or revascularization rates compared to aspirin alone.
  • Net adverse clinical events were higher in the ticagrelor-plus-aspirin group, occurring in 9.1% of patients versus 6.4%.
  • This open-label, registry-based clinical trial involved 2201 patients across 22 Nordic centers, with a follow-up of 1 year.
  • Major bleeding incidence was significantly higher among patients in the ticagrelor group, indicating potential risk.

Cite This Study

Jeppsson et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477d3dbhttps://doi.org/10.1056/nejmoa2508026
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual antiplatelet therapy with aspirin and ticagrelor vs aspirin alone in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery: a systematic review and meta-analysis2026
  2. 2‘Aspirin versus ticagrelor for the management after coronary revascularization - a systematic review and meta‑analysis of randomised trials’2026
  3. 3Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial2018 · 797 citations
  4. 4Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes2020 · 55 citations
  5. 5Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis2025